gutflix
GI learning, personalised

Summary

TOFACITINIB-INDUCED EOSINOPHILIA – FIRST CASE REPORT

Cidalina Caetano

UEG Week Copenhagen 2023 | Poster

IBD

October 15, 2023

Case report describes recurrent eosinophilia and acute kidney injury in an 18-year-old woman with ulcerative colitis following tofacitinib initiation, resolving with drug suspension and recurring upon rechallenge.

KEY POINTS

- An 18-year-old woman with left-sided ulcerative colitis refractory to infliximab and vedolizumab developed peripheral eosinophilia (3000 cells/mm3) and grade 1 acute kidney injury within 6 days of starting tofacitinib.
- Temporary suspension of tofacitinib led to rapid normalization of renal function and eosinophil levels, but rechallenge after 2 days resulted in recurrent moderate eosinophilia (2000 cells/mm3).
- Permanent discontinuation of tofacitinib resolved the eosinophilia, and the patient achieved clinical and biochemical remission with high-dose corticosteroids, ustekinumab every 4 weeks, and tacrolimus.
- Three-month follow-up showed no recurrence of eosinophilia after tofacitinib discontinuation.
- The authors propose this as the first reported case of tofacitinib-induced eosinophilia in ulcerative colitis, suggesting a possible type IVb hypersensitivity reaction.

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/98147f2e-743c-11ee-9cf6-0242ac140004

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.